Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Harun Fajkovic; Romain Mathieu; Ilaria Lucca; Manuela Hiess; Nicolai Hübner; Bashir Al Hussein Al Awamlh; Richard Lee; Alberto Briganti; Pierre Karakiewicz; Yair Lotan; Morgan Roupret; Michael Rink; Luis Kluth; Wolfgang Loidl; Christian Seitz; Tobias Klatte; Gero Kramer; Martin Susani; Shahrokh F. Shariat

doi:10.1016/j.urolonc.2015.10.013

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Harun Fajkovic, Romain Mathieu, Ilaria Lucca, Manuela Hiess, Nicolai Hübner, Bashir Al Hussein Al Awamlh, Richard Lee, Alberto Briganti, Pierre Karakiewicz, Yair Lotan, Morgan Roupret, Michael Rink, Luis Kluth, Wolfgang Loidl, Christian Seitz, Tobias Klatte, Gero Kramer, Martin Susani, Shahrokh F. Shariat

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort. Material and methods: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR. Results: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P

Original language	English
Journal	Urologic Oncology: Seminars and Original Investigations
DOIs	https://doi.org/10.1016/j.urolonc.2015.10.013
Publication status	Accepted/In press - Sep 14 2015

Keywords

Biochemical recurrence
Localized prostate cancer
Lymphovascular invasion
Radical prostatectomy

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2015.10.013

Cite this

Fajkovic, H., Mathieu, R., Lucca, I., Hiess, M., Hübner, N., Al Awamlh, B. A. H., Lee, R., Briganti, A., Karakiewicz, P., Lotan, Y., Roupret, M., Rink, M., Kluth, L., Loidl, W., Seitz, C., Klatte, T., Kramer, G., Susani, M., & Shariat, S. F. (Accepted/In press). Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2015.10.013

Fajkovic, H, Mathieu, R, Lucca, I, Hiess, M, Hübner, N, Al Awamlh, BAH, Lee, R, Briganti, A, Karakiewicz, P, Lotan, Y, Roupret, M, Rink, M, Kluth, L, Loidl, W, Seitz, C, Klatte, T, Kramer, G, Susani, M & Shariat, SF 2015, 'Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy', Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2015.10.013

@article{17f75d7e9c354613a94dccb4be24dd6d,

title = "Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy",

abstract = "Objective: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort. Material and methods: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR. Results: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P",

keywords = "Biochemical recurrence, Localized prostate cancer, Lymphovascular invasion, Radical prostatectomy",

author = "Harun Fajkovic and Romain Mathieu and Ilaria Lucca and Manuela Hiess and Nicolai H{\"u}bner and {Al Awamlh}, {Bashir Al Hussein} and Richard Lee and Alberto Briganti and Pierre Karakiewicz and Yair Lotan and Morgan Roupret and Michael Rink and Luis Kluth and Wolfgang Loidl and Christian Seitz and Tobias Klatte and Gero Kramer and Martin Susani and Shariat, {Shahrokh F.}",

year = "2015",

month = sep,

day = "14",

doi = "10.1016/j.urolonc.2015.10.013",

language = "English",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

AU - Fajkovic, Harun

AU - Mathieu, Romain

AU - Lucca, Ilaria

AU - Hiess, Manuela

AU - Hübner, Nicolai

AU - Al Awamlh, Bashir Al Hussein

AU - Lee, Richard

AU - Briganti, Alberto

AU - Karakiewicz, Pierre

AU - Lotan, Yair

AU - Roupret, Morgan

AU - Rink, Michael

AU - Kluth, Luis

AU - Loidl, Wolfgang

AU - Seitz, Christian

AU - Klatte, Tobias

AU - Kramer, Gero

AU - Susani, Martin

AU - Shariat, Shahrokh F.

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Objective: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort. Material and methods: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR. Results: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P

AB - Objective: To validate the impact of lymphovascular invasion (LVI) on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) in a large multiinstitutional cohort. Material and methods: Retrospective data from 6,678 patients treated with a RP and bilateral lymphadenectomy for prostate cancer (PC) from 8 centers were collected. The primary endpoint was BCR. Results: Overall, 767 patients (11.5%) had LVI. Patients with LVI had significantly higher Gleason scores (P = 0.01). After a median follow-up of 28 months (interquartile range: 21-44), patients with LVI had a 1.66 fold increased risk of BCR (P

KW - Biochemical recurrence

KW - Localized prostate cancer

KW - Lymphovascular invasion

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84959881608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959881608&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2015.10.013

DO - 10.1016/j.urolonc.2015.10.013

M3 - Article

AN - SCOPUS:84959881608

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

ER -

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this